Patents by Inventor Bart Vanderhoydonck

Bart Vanderhoydonck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12378202
    Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
    Type: Grant
    Filed: December 23, 2022
    Date of Patent: August 5, 2025
    Assignees: SPRINGWORKS THERAPEUTICS, INC., KATHOLIEKE UNIVERSITEIT LEUVEN, VIB VZW
    Inventors: Bart Vanderhoydonck, Arnaud Marchand, Aurélie Candi, Matthias Versele
  • Publication number: 20250115574
    Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
    Type: Application
    Filed: June 5, 2024
    Publication date: April 10, 2025
    Inventors: Bart VANDERHOYDONCK, Arnaud MARCHAND, Stephen L. GWALTNEY, II, Stéphane SPIESER, Wim SMETS, Aurélie CANDI, Matthias VERSELE, Georg HALDER
  • Publication number: 20240417398
    Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
    Type: Application
    Filed: May 16, 2024
    Publication date: December 19, 2024
    Inventors: Brian LAWHORN, Arnaud MARCHAND, Bart VANDERHOYDONCK, Stephen L. GWALTNEY, Stéphane SPIESER
  • Publication number: 20240409556
    Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
    Type: Application
    Filed: May 16, 2024
    Publication date: December 12, 2024
    Inventors: Brian LAWHORN, Stephen L. GWALTNEY, II, Arnaud MARCHAND, Bart VANDERHOYDONCK
  • Publication number: 20240383891
    Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.
    Type: Application
    Filed: May 16, 2024
    Publication date: November 21, 2024
    Inventors: Brian LAWHORN, Arnaud MARCHAND, Bart VANDERHOYDONCK, Stephen L. GWALTNEY, II
  • Patent number: 12030866
    Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
    Type: Grant
    Filed: December 23, 2022
    Date of Patent: July 9, 2024
    Assignees: SPRINGWORKS THERAPEUTICS, INC., KATHOLIEKE UNIVERSITEIT LEUVEN, VIB VZW
    Inventors: Bart Vanderhoydonck, Arnaud Marchand, Stephen L. Gwaltney, Stéphane Spieser, Wim Smets, Aurélie Candi, Matthias Versele, Georg Halder
  • Publication number: 20240025856
    Abstract: The present invention relates to novel compounds of formula (Ia), to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to processes for the preparation of said compounds.
    Type: Application
    Filed: September 30, 2021
    Publication date: January 25, 2024
    Inventors: Arnaud MARCHAND, Aurélie CANDI, Bart VANDERHOYDONCK, Matthias VERSELE, Stephen L. GWALTNEY, II
  • Publication number: 20240018148
    Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.
    Type: Application
    Filed: February 2, 2023
    Publication date: January 18, 2024
    Inventors: Bart VANDERHOYDONCK, Arnaud MARCHAND, Wim SMETS, Aurélie CANDI, Matthias VERSELE
  • Publication number: 20230391726
    Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.
    Type: Application
    Filed: February 24, 2023
    Publication date: December 7, 2023
    Inventors: Bart VANDERHOYDONCK, Arnaud MARCHAND, Aurélie CANDI, Matthias VERSELE
  • Publication number: 20230279016
    Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
    Type: Application
    Filed: December 23, 2022
    Publication date: September 7, 2023
    Inventors: Bart VANDERHOYDONCK, Arnaud MARCHAND, Stephen L. GWALTNEY, II, Wim SMETS, Aurélie CANDI, Matthias VERSELE, Amuri KILONDA
  • Publication number: 20230278982
    Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
    Type: Application
    Filed: December 23, 2022
    Publication date: September 7, 2023
    Inventors: Bart VANDERHOYDONCK, Arnaud MARCHAND, Stephen L. GWALTNEY, II, Stéphane SPIESER, Wim SMETS, Aurélie CANDI, Matthias VERSELE, Georg HALDER
  • Publication number: 20230278962
    Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
    Type: Application
    Filed: December 23, 2022
    Publication date: September 7, 2023
    Inventors: Bart VANDERHOYDONCK, Arnaud MARCHAND, Aurélie CANDI, Matthias VERSELE
  • Publication number: 20230202985
    Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
    Type: Application
    Filed: December 23, 2022
    Publication date: June 29, 2023
    Inventors: Bart VANDERHOYDONCK, Arnaud MARCHAND, Stephen L. GWALTNEY, II, Stéphane SPIESER, Wim SMETS, Aurélie CANDI, Matthias VERSELE
  • Publication number: 20230203035
    Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
    Type: Application
    Filed: December 23, 2022
    Publication date: June 29, 2023
    Inventors: Bart VANDERHOYDONCK, Arnaud MARCHAND, Aurélie CANDI, Matthias VERSELE
  • Publication number: 20180201622
    Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (IA) or (IB), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase III? (PI4KIII?) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Application
    Filed: March 16, 2018
    Publication date: July 19, 2018
    Inventors: Daniel James Ford, Qiuya Huang, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck
  • Patent number: 10000497
    Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (I), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase III? (PI4KIII?) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: June 19, 2018
    Assignees: UCB BIOPHARMA SPRL, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D
    Inventors: Helen Tracey Horsley, Qiuya Huang, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck
  • Patent number: 9969748
    Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (IA) or (IB), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase III? (PI4KIII?) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: May 15, 2018
    Assignees: UCB Biopharma SPRL, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Daniel James Ford, Qiuya Huang, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck
  • Patent number: 9730944
    Abstract: The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: August 15, 2017
    Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Steven De Jonghe, Ling-Jie Gao, Piet Herdewijn, Jean Herman, Miyeon Jang, Pieter Leyssen, Thierry Louat, Johan Neyts, Christophe Pannecouque, Bart Vanderhoydonck
  • Patent number: 9714248
    Abstract: A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 25, 2017
    Inventors: Daniel James Ford, Richard Jeremy Franklin, Anant Ramrao Ghawalkar, Helen Tracey Horsley, Qiuya Huang, James Thomas Reuberson, Bart Vanderhoydonck
  • Patent number: RE48622
    Abstract: A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: July 6, 2021
    Assignees: UCB Biopharma SRL, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Daniel James Ford, Richard Jeremy Franklin, Anant Ramrao Ghawalkar, Helen Tracey Horsley, Qiuya Huang, James Thomas Reuberson, Bart Vanderhoydonck